☆
Adjuvant chemotherapy and overall survival in premenopausal women with HR+/HER2 − early breast cancer: a national cancer database analysis in the era of genomic testing and CDK4/6 inhibitors
Nerea Lopetegui-Lia, Yevgeniya Gokun, Ashley Pariser Davenport, Arya Mariam Roy, Erin Burke, Therese Youssef Andraos, Doreen Marie Agnese, Heather Marie LeFebvre, Brandon Slover, Margaret Gatti-Mays, Kai C.C. Johnson, Daniel G. Stover, Sara P Myers
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Purpose Genomic assays guide adjuvant treatment decisions in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, yet contemporary treatment patterns and outcomes among premenopausal women remain...
☆
Trends in the use of radiation therapy for second primary breast cancer
Frederick Song, Angela C. Tramontano, Michael J. Hassett, Laura Dominici, Hajime Uno, Rinaa S. Punglia
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Updated insights into breast cancer survival disparities by race/ethnicity and HR/HER2 molecular subtypes: a Florida population-based analysis
Amber N. Balda, Hannah M. Cranford, Carmen Calfa, Frank J. Penedo, Paulo S. Pinheiro
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Purpose To evaluate differences in breast cancer-specific survival (BCSS) overall and across molecular subtypes defined by hormone receptor and HER2 status, and by racial/ethnic groups. Methods The population-based analysis...
☆
Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study
Zhe Wang, Liu Yang, Pu Du, Ge Zhao, Lan Hou, Yuan Qin, Huan Zhang, Zelin Tian, Yike Li, Mingkun Zhang, Juliang Zhang
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Rechallenge, switch, or target? navigating advanced breast cancer after adjuvant CDK 4/6 inhibitors
Fausto Petrelli, Antonio Ghidini, Maria Chiara Parati, Mara Ghilardi, Karen Borgonovo, Lorenzo Dottorini
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Computed tomography derived cardiometabolic biomarkers in high-risk breast cancer using fully automated deep learning algorithms
Terrence C. Tsou, Zhao Yang, Tingchang Wang, Hanfei Qi, Amanda Blackford, Kala Visvanathan, Ronald M. Summers, Jennifer Y. Sheng
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Survival benefit of adding carboplatin to standard anthracycline–taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis
Ying Wu, Lifeng Kong, Ejakpovi Emmanuel Oghenefejiro, Xuan Cao, Deqian Wang, Chenmeng Tao, Xiangyang Wang, Rong Qin, Yao Ji, Liang Yin
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Circulating miR-125b-5p and miR-210-3p are reduced in long-term breast cancer survivors with cardiovascular disease
Mariaconcetta Sicurella, Juana Maria Sanz, Valeria Raparelli, Domenico Sergi, Alessandro Greatti, Chiara Ghirardini, Anna Dipinto, Noemi Mindicini, Riccardo Spaggiari, Luana Calabrò, Luca Maria Neri, Angelina Passaro
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Association between screen-detected health-related social needs and nonadherence to endocrine therapy in patients with nonmetastatic breast cancer: an observational study
Nadia Liyanage-Don, David DeStephano, Claire Sathe, Shing Lee, Melissa Beauchemin, Melissa Accordino, Dawn Hershman, Ian M. Kronish
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial
Mingkun Zhang, Yuan Qin, Junhao Wan, Zelin Tian, Ziyu Zhang, Xulong Zhu, Dong Fan, Liu Yang, Lan Hou, Huan Zhang, Ge Zhao, Ting Wang, Juliang Zhang
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials
Hala Aboushawareb, Abdelrhman W. Mohamed, Hamzah M. Alghzawi, Abdelrahman El Helbawy, Aanab Tarig, Huthayfa Zatari, Mohanad mahmoud Hekal, Islam Hasan, Ahmed Yasser Shaban
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Background HER2-positive breast cancer is a distinct subtype associated with less favorable outcomes without targeted therapy. Dual HER2 blockade with pertuzumab and trastuzumab has shown improved efficacy compared to...
☆
Real-world patient experiences in HR+/HER2- metastatic breast cancer: a study of symptom and side effect reporting by patients and physicians
Celeste K. Nsubayi, Gregory A. Vidal, Allison W. Kurian, M. K. Rehnquist, Cosmina Hogea, Nikoleta Sjekloca, Anandaroop Dasgupta, Annabel Lambert, Chloe Hammond, Stephanie L. Graff, Andrea N. Curry
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Chemoendocrine therapy versus tamoxifen with ovarian function suppression in women with node-positive breast cancer
Yung-Huyn Hwang, Sae Byul Lee, Jisun Kim, Il Yong Chung, BeomSeok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Tae-Kyung Robyn Yoo
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
The landscape of cell surface target expression in treatment resistant early-stage breast cancer
Per Karlsson, Marina N. Sharifi, Erik Holmberg, Hamza Bakhtiar, Emma Niméus, Fredrika Killander, Martin Sjöström, Shuang G. Zhao
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Purpose Disease recurrence after definitive therapy remains a major cause of morbidity and mortality in early-stage breast cancer, with limited options for treatment intensification. Cell surface–targeted (CST) therapies,...
☆
Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
P. V. B. D. Cerqueira, F. A. B. Campos, S. M. Caputo, E. Rouleau, H. K. Mantovani, L. R. da Silva, A. L. Cicilini, S. M. Sanches, F. Makdissi, A. A. B. A. da Costa, M. De Brot, C. Osório, V. Castro Vasconcelos, V. Cordeiro de Lima, J. C. Casali da rocha, D. Carraro, G. Torrezan, E. Santana dos Santos
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Purpose Male breast cancer is rare, and data on its clinicopathological and germline characteristics remain scarce. Our objective was to describe the clinicopathological profile of men with breast cancer and to estimate the...
☆
Co-payments and adherence to endocrine therapy among Medicaid beneficiaries with breast cancer
Caitlin C. Murphy, Dyanna Gregory, Betsy Q. Cliff, Andrea C. Betts, Caroline L. Kirk, Sandi L. Pruitt, Anna Tavakkoli, Jasmin A. Tiro
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Purpose Prescription co-payments are associated with adherence to endocrine therapy among Medicare- and commercially insured-women, but the impact among Medicaid beneficiaries—who typically have no or minimal co-payments—is not...
☆
Effects of digital stress-management interventions in breast cancer patients 18 months after intervention access
Karianne Svendsen, Lise Solberg Nes, Sigrid Leithe, Anders Meland, Ylva M. Gjelsvik, Elin Børøsund, Tor Åge Myklebust, Aina Balto, Christine M. Rygg Hoksnes, Cecilie E. Kiserud, Michael H. Antoni, Trudie Chalder, Ingvil Mjaaland, Linda E. Carlson, Hege R. Eriksen, Giske Ursin
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Clinicopathological differences between asymptomatic vs symptomatic breast cancer: a 30-year single-center retrospective study
Bomi Yi, Cholong Kim, Young-Jin Lee, Sae Byul Lee, Il Yong Chung, Hee Jeong Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Tae-Kyung Robyn Yoo, Jisun Kim
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic
Joy Zeynoun, Madeline Evans, Kimberly Boldig, Haythem Ali
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
Abstract Purpose Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) breast cancer accounts for approximately 65–70% of all breast cancer cases. First-line treatment for metastatic HR+/HER2– disease...
☆
Brain as a site of first recurrence after adjuvant therapy for early breast cancer: mining the hellenic cooperative oncology group database-The BRACE study
Evangelia Razis, Kyriaki Papadopoulou, Nikolaos Korfiatis, Christos Christodoulou, Helen P. Kourea, Anna Goussia, Olympia Tzaida, Anna Batistatou, Andreas Mamilos, Christos Markopoulos, Vasileios Venizelos, Grigorios Xepapadakis, Pantelis Skarlos, George Pentheroudakis, Dimitrios Pectasides, Angelos Koutras, Athina Christopoulou, Amanda Psyrri, Helen Gogas, Flora Zagouri, George Fountzilas
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Acceptability of a patient support and educational intervention for black breast cancer survivors
Destiny Harden, Amy Comander, Hannah Lee, Nebulla V. Stephen, Anne K. Buck, Audra Hite Morris, Naomi Y. Ko, Erica T. Warner
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Venous thromboembolism after breast cancer surgery: incidence, predictive factors and outcomes in 270,564 patients
Samuel A. Knoedler, Adriano Fabi, Pushpamali De Silva, Sabrina Sy, Constanze Elfgen, Martin Heidinger, Sebastian R. Griewing, Giuseppe Sofo, Daniel Schmauss, Christoph Tausch, Giacomo Montagna, Stefan O. P. Hofer, Florian Falkner, Elisabeth A. Kappos, Dennis P. Orgill, Arash Momeni
Breast Cancer Research and Treatment
· Онкология
· 2026-11-01
☆
Sociodemographic and clinicopathologic features associated with rapid relapse in triple-negative breast cancer: a Swedish nationwide registry-based study
Sithumini Sarathchandra, Jenny Nyqvist-Streng, Elin Sahlberg, Zakaria Einbeigi, Khalil Helou, Anikó Kovács, Slavica Janeva, Per Karlsson, Toshima Z. Parris
Breast Cancer Research and Treatment
· Онкология
· 2026-10-28
Abstract Purpose To characterize clinicopathologic, treatment-related, and sociodemographic factors associated with rapid versus late relapse in triple-negative breast cancer (TNBC), and to evaluate how relapse timing influences...
☆
Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India
Ayesha Mahajan, Soumya Surath Panda, Lalatendu Moharana, M.V. Chandrakanth, Vivek Agarwala, Rupam Manna, S.V. Saju, Susan Honey Raju, Prasanth Ganesan, Gomathi Shankar, Ashwin Oommen Phillip, Sunu Lazar Cyriac, Anil Jose, P. Unnikrishnan, Kanu Priya Bhatia, Amit Sehrawat, Deepak Sundriyal, Himani Dhanai, Lipsita Samantaray, Swati Sucharita Mohanty, Biswajit Dubashi
Breast Cancer Research and Treatment
· Онкология
· 2026-10-28
☆
Risk of malignancy after diagnosis of radial sclerosing lesion with associated atypia
Lorena Beatriz Delgado Casanova, Sagar Dhamne, Erika Resetkova, Mary S. Guirguis, Yimin Geng, Therese Bartholomew Bevers, Isabelle Bedrosian, Lei Huo, Kerollos Nashat Wanis
Breast Cancer Research and Treatment
· Онкология
· 2026-10-26
☆
GLP-1 receptor agonist–associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis
Keri Morgan Cronin, Amy Tiersten
Breast Cancer Research and Treatment
· Онкология
· 2026-10-26
☆
Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice
Claire E. Smith, Avina Rami, Tianyu Li, Nabihah Tayob, Pooja Patel, Harold J. Burstein, Sandra McAllister, Rachel Abelman, Rachel A. Freedman
Breast Cancer Research and Treatment
· Онкология
· 2026-10-26
☆
Circulating tumor cells in lobular versus ductal metastatic breast cancer
Emily M. Dolce, Elizabeth P. Darga, Nicholas C. Henderson, Dafydd G. Thomas, David A. Hanauer, Arul M. Chinnaiyan, Erin F. Cobain, N. Lynn Henry, Costanza Paoletti, Andi K. Cani, Daniel F. Hayes
Breast Cancer Research and Treatment
· Онкология
· 2026-10-26
Abstract Purpose Infiltrating lobular carcinoma (ILC) accounts for ~ 10% of all invasive breast cancer histologies. ILC is associated with worse prognosis than infiltrating ductal cancer. Circulating tumor cells (CTCs) are commonly...
☆
Change in alcohol consumption and all-cause mortality among postmenopausal women diagnosed with breast cancer
Samantha Rees, Clara Bodelon, Saptarshi Chakraborty, Amy E. Millen, Ying Wang, Kierstin Faw, Lauren R. Teras, Marissa M. Shams-White, Alpa V. Patel, Jo L. Freudenheim
Breast Cancer Research and Treatment
· Онкология
· 2026-10-23
Abstract Purpose Evidence is inconsistent regarding an association between alcohol consumption and survival following a breast cancer diagnosis; therefore, we examined how change in alcohol consumption affects all-cause mortality (ACM)...
☆
Recent trends in race and ethnicity reporting in breast surgery journals
Omar Font-Torres, Shahenda Khedr, Victoria Ende, Julie Hong, Xiaoyue Ma, Daniella Abramov, Anisa Raidah, Janice Zhang, Angela Colback, Jonaki Debi, Manmeet Malik, Vivian Bea, Lisa Newman, Daithi S. Heffernan, Steven Chao, Tammy Ju
Breast Cancer Research and Treatment
· Онкология
· 2026-10-23